CytoAgents Completes Cohort 1 Dose-Escalation in Clinical Phase 1B for Cytokine Release Syndrome Research
April 26, 2025
CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first